New Prospects in Blood-based Biomarkers and Disease-Modifying Anti-Amyloid Antibody Therapies for Early-Stage Alzheimer’s Disease

CME | 1.50 Credits

Webcast

Time to Complete: 90 minutes

Released: February 16, 2024

Expires: February 16, 2025

Maximum Credits:
1.50 / AMA PRA Category 1 Credits^TM

Program Description

This webcast provides an update on the blood-based markers (BBMs) improve randomized clinical trials (RCTs) design and conduct of Alzheimer’s disease. It remains to be determined if the data available on BBMs are strong enough to replace CSF and PET biomarkers as entry criteria and monitoring tools in RCTs. Strategies to optimize and guide disease-modifying anti-amyloid antibody (AAA) therapies based on BBMs in managing patients with early-stage AD.

Intended Audience

Neurologists, nurse practitioners, and physician assistants involved in Alzheimer’s disease patient care.

Commercial Supporter

This activity is supported by an educational grant from Eisai, Inc.

Educational Objectives

Upon completion of the educational activity, participants should be able to:

• Assess the blood-based biomarkers in diagnosing early-stage AD and its utility in the prevention.
• Identify strategies to optimize disease-modifying anti-amyloid antibody (AAA) therapies in managing patients with early-stage AD.

Accredited Providers

The University of Cincinnati, Amedco, and MedNet have collaborated to design and execute this activity.

Physicians (ACCME) Credit

Additional Credit Information

Through an agreement between the American Medical Association (AMA) and the European Union of Medical Specialists, physicians and healthcare providers may convert CME/CE PRA Category 1 Credits^TM to an equivalent number of European CME Credits^® (ECMECs^®). The UEMS-EACCME^® has mutual recognition agreements with the AMA for live events and e-learning materials.

Physician Assistants/Associates
PAs may claim a maximum of 1.50 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)^TM from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.50 hours.

Disclosures of Relationships with Ineligible Companies Policy

It is the policy of the Amedco to ensure activity content is balanced, independent, objective, and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member, and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Planners and Managers Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

All relevant relationships have been reviewed and mitigated.

Kamatham A. Naidu, PhD (MedNet), has no relevant financial relationships
Brian Waggoner (MedNet) has no relevant financial relationships to disclose.
Sheryl Morgan (Amedeo) has no relevant financial relationships to disclose.

Off-Label Disclosure Statement

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Faculty

Jeremy Pruzin MD
Cognitive/Behavioral Neurologist
Banner Alzheimer’s Institute
Phoenix, AZ

Dr. Pruzin discloses that he is on the advisory board of Eisai, Inc.

Marwan Noel Sabbagh MD, FAAN, FANA
Moreno Family Chair of Alzheimer’s Research
Vice Chair for Research and Professor of Neurology
Director of the Applied Alzheimer’s Research Laboratory
Phoenix, AZ

Dr. Sabbagh discloses the following:
Ownership interest (Stock or stock options): NeuroTau, Optimal Cognitive Health Company, uMethod Health, Versanum, Athira, TransDermix, Seq BioMarque, NeuroReserve, Lighthouse Pharmaceuticals, Alzheon, Reservoir Neuroscience
Consulting: Roche-Genentech, Eisai, Lilly, Synaptogenix, NeuroTherapia, T3D, Signant Health, Novo Nordisk, Corium, Prothena, KeiferRx, Anavex, Cognito Therapeutics
Royalties: Humanix
Board of Director: EIP Pharma
Grants and other Support:
PI: RO 1 AG059008
SABBAGH, MARWAN (PI)
09/01/18-05/31/24
A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease

LBDA1811MS
SABBAGH, MARWAN (PI)
05/15117-04/30/23
Research Center of Excellence (RCOE) designation

Site PI TRC-DS 1R61AG066543-01 (R61AG066543)
Site PI:ADRC- 1P30AG072980-01
Site PI: ADNI-U19AG024904

GC-2013717
SABBAGH, MARWAN (PI)
01/01/23-12/31127
Assessment of Lenalidomide for Alzheimer’s Disease

R01 AG073212
SABBAGH, MARWAN (PI)
WILSON, JEFFREY (MPI)
DECOURT, BORIS (MPI)
Repurposing Siponimod for Alzheimer’s Disease
4/1/21- 3/30/26

Instructions

In order to receive CME/CE credits, participants must complete the pre-assessment questions, post-assessment, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript, which you can access at any time.

ANCC – Amedco
Phone Number: 651-789-3730
E-Mail: Sheryl@AmedcoEmail.com

Privacy Policy

myCME privacy policy